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ORIGINAL RESEARCH REPORT
A Simple, Cost-Effective but Highly Efficient System
for Deriving Ventricular Cardiomyocytes
from Human Pluripotent Stem Cells
Zhihui Weng,1,2 Chi-Wing Kong,1,2 Lihuan Ren,1,2 Ioannis Karakikes,3 Lin Geng,1,2 Jiaozi He,1,4
Maggie Zi Ying Chow,1,2 Chong Fai Mok,1,2 Wendy Keung,1,2 Howard Chow,5
Anskar Y. H. Leung,1,5 Roger J. Hajjar,3 Ronald A. Li,1–3,5 and Camie W. Chan1,4,5
Self-renewable human pluripotent stem cells (hPSCs) serve as a potential unlimited ex vivo source of human
cardiomyocytes (CMs) for cell-based disease modeling and therapies. Although recent advances in directed
differentiation protocols have enabled more efficient derivation of hPSC-derived CMs with an efficiency of
*50%–80% CMs and a final yield of*1–20 CMs per starting undifferentiated hPSC, these protocols are often
not readily transferrable across lines without first optimizing multiple parameters. Further, the resultant pop-
ulations are undefined for chamber specificity or heterogeneous containing mixtures of atrial, ventricular (V),
and pacemaker derivatives. Here we report a highly cost-effective and reproducibly efficient system for deriving
hPSC-ventricular cardiomyocytes (VCMs) from all five human embryonic stem cell (HES2, H7, and H9) and
human induced PSC (hiPSC) (reprogrammed from human adult peripheral blood CD34+ cells using non-
integrating episomal vectors) lines tested. Cardiogenic embryoid bodies could be formed by the sequential
addition of BMP4, Rho kinase inhibitor, activin-A, and IWR-1. Spontaneously contracting clusters appeared as
early as day 8. At day 16, up to 95% of cells were cTnT+ . Of which, 93%, 94%, 100%, 92%, and 92% of
cardiac derivatives from HES2, H7, H9, and two iPSC lines, respectively, were VCMs as gauged by signature
ventricular action potential and ionic currents (INa
+ /ICa,L
+ /IKr
+ /IKATP
+ ); Ca2 + transients showed positive
chronotropic responses to b-adrenergic stimulation. Our simple, cost-effective protocol required the least
amounts of reagents and time compared with others. While the purity and percentage of PSC-VCMs were
comparable to a recently published protocol, the present yield and efficiency with a final output of up to 70
hPSC-VCMs per hPSC was up to 5-fold higher and without the need of performing line-specific optimization.
These differences were discussed. The results may lead to mass production of hPSC-VCMs in bioreactors.
Introduction
Self-renewable human (h) pluripotent stem cells(PSCs), including embryonic stem cells (ESCs) and in-
duced PSCs (iPSCs), serve as a potential unlimited ex vivo
source of human cardiomyocytes (CMs) for cell-based ther-
apies, disease modeling, and other applications such as drug
discovery and cardiotoxicity screening. Recent advances in
directed cardiac differentiation protocols [1–7] have enabled
the derivation of hESC/iPSC-CMs with yields several orders
of magnitude higher than those of traditional methods, such
as ‘‘spontaneous’’ embryoid body (EB) formation [8,9] and
endodermal coculture [10,11]. Using defined serum-free
media in combination with cocktails of such growth factors
required for normal cardiogenesis as bone morphogenetic
proteins (BMPs), activin-A, Wnt agonists and antagonists,
fibroblast growth factor 2 (FGF2), and vascular endothelial
growth factor (VEGF), and Dickkopf-related protein (DKK),
these protocols can generate*40%–90% cardiac troponin T
(cTnT) + CMswith a final yield ranging from 1 to 20 CMs per
starting undifferentiated hPSC [2–4,12,13]. However, they
often require PSC-line-dependent titrations of multiple pa-
rameters (eg, BMP4 and activin-A concentrations) [1,14,15]
and other specific needs (eg, sandwich matrix) [2], particu-
larly for hiPSC lines that tend to be more variable [16].
Further, while relatively effective for generating cardiac
cells, the resultant populations are undefined for chamber
specificity [4,5,13] or heterogeneous containing mixtures of
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atrial, ventricular (V), and pacemaker derivatives [17]. Here
we report a highly cost-effective and reproducibly efficient
system for deriving hPSC-ventricular cardiomyocytes (VCMs)
from all the five hESC (HES2, H7, and H9) and iPSC (re-
programmed from adult peripheral blood CD34+ cells using
non-integrating episomal vectors) lines tested.
Materials and Methods
hiPSC and ESC culture
hiPSC lines were derived from adult peripheral blood
CD34+ cellsusing thenon-integratedepisomalvectorspCXLE-
hOCT3/4-shp53, pCXLE-hSK, and pCXLE-hUL [18]. Briefly,
CD34 + cells were purified (> 95% purity) from anonymous
donors and expanded in StemSpan H3000 (Stemcell Tech-
nologies) with the cytokine cocktail CC100 (Stemcell Tech-
nologies) for 3 days. Cells were nucleofectedwith the episomal
vectors using the Human CD34 Cell Nucleofector kit
(Amaxa) according to the manufacturer’s protocol. After 72 h,
cells were transferred to Matrigel (BD Biosciences)-coated
plates inmTeSR1medium (STEMCELLTechnologies).Mor-
phological changes were observed a few days later. Colonies
resembling hPSCs typically started to appear on day 7, and
were picked on day 13 after nucleofection. H7 (WiCell),
H9DF, (a kind gift fromDr. JosephWu),HES2 (ESI) (passages
35–55) hESC and hiPSC lines were maintained in feeder- and
serum-free condition inmTeSR1mediumonMatrigel at 37C
in 5% CO2 in a humidified normoxic environment.
hiPSC validation
To characterize hiPSC clones, cultured cells were fixed
by 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 15min, followed by permeabilization by 0.1%
Triton X-100 for 15min, and washing with PBS for three
times. The fixed samples were stained with anti-OCT4,
SSEA-4, and Tra-1-81 for 2 h at room temperature (RT)
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/scd) and then with flur-
ochrome-conjugated goat anti-rabbit or anti-mouse second-
ary antibodies for 1 h. To test for pluripotency, hiPSCs were
differentiated to form EBs in DMEM/F12 (Life Technolo-
gies) with 20% Knockout Serum Replacement (Life Tech-
nologies), 2mM nonessential amino acids, 2mM l-glutamine,
and 0.1mM b-mercaptoethanol. At day 15, EBs were stained
for markers of the three germ layers (ie, Tuji, SMA, and
AFP). For teratoma formation, 1 · 106 iPSCs were injected
subcutaneously into NOD/SCID immunodeficient mice. Ter-
atomas were harvested and stained 7–9 weeks after injection
for H&E staining. Karyotyping was done according to a
published protocol [19].
Direct ventricular cardiomyocyte differentiation
Undifferentiated hPSCs were digested into smaller clus-
ters using Dispase (STEMCELL Technologies) and seeded
onto Matrigel-coated plates at *3 · 105 cells/10 cm2 in
mTeSR1 medium for 4 days until they were *80%–90%
confluence on D0 (Fig. 1). To initiate cardiac differentiation,
hPSCs were digested into single-cell suspensions in ultra-
low-attachment six-well plates (Corning) using Accutase
(Invitrogen) and cultured in mTeSR1 medium with Matrigel
(40 mg/mL) with BMP4 (1 ng/mL; Invitrogen) and Rho ki-
nase inhibitor (ROCK) (10mM; R&D) under a hypoxic
condition with 5% O2. Twenty-four hours later, the culture
was washed and replaced in StemPro34 SFM (Invitrogen)
with ascorbic acid (AA, 50mg/mL; Sigma), 2mM Gluta-
MAX-1 (Invitrogen), BMP4 (10 ng/mL), and human re-
combinant activin-A (10 ng/mL; Invitrogen) for 3 days. On
day 4, IWR-1, a Wnt inhibitor (5 mM; Enzo Life Sciences),
was added. Cardiac mesodermal cells developed into func-
tional contracting clusters could be detected as early as day
8. On day 8, cells were transferred to a normoxic environ-
ment and maintained in StemPro34 SFM+AA medium for
further characterization. In some cases, the cardiac mixtures
(30–50 days old) were transduced with the recombinant
lentivirus (LV)-MLC2v-Tdtomato-T2A-Zeo. MLC2v-positive
cells were selected using the antibiotic Zeocin.
Immunostaining for CMs and flow cytometry
analysis
For immunostaining of cardiac cells, beating clusters (be-
tween 16 and 35 days of differentiation) were digested into
single cells and immunostained with anti-cTnT, sarcomeric, a-
actinin, connexin 43, COXIV, myosin heavy chain (MF20),
two isoforms of myosin light chain 2, MLC2a, and MLC2v
antibodies listed in Supplementary Table S1. Primary anti-
bodies were diluted in PBS with 1% BSA and incubated at RT
for 2 h. Alexa Fluor (AF)488-conjugated goat anti-mouse IgG
or AF555 anti-mouse IgG (Invitrogen) were used as secondary
antibodies and stained for 1 h at RT. Coverslips were mounted
onto glass slides in ProlongGoldmountingmediumwithDAPI
(Invitrogen) and samples were imaged on LSMCarl Zeiss 510
Meta (Carl Zeiss) or Nikon Eclipse TiS microscope. For flow
cytometry, cells were digested and resuspended in PBS with
2% FBS. To stain for intracellular markers, cells were fixed,
permeabilized, and stained with antibodies against various
cardiac markers. To measure cardiac differentiation, percent-
ages of CMs were estimated based on the % of cTnT-positive
cells at differentiation days 16–18.
Metabolic stress and mitochondrial membrane
potential
Mitochondrial membrane potential in HES2-VCMs was
measured with the potential-sensitive dye JC-1 (Invitrogen).
LV-MLC2v-Tdtomato-T2A-Zeo–transduced and Zeo-selected
HES2-VCMs (30–50 days old) were incubated at 37C with
0.5 mM JC-1 in serum-free DMEM for 15min. To simulate
metabolic oxidative stress, HES2-VCMs were treated with
hydrogen peroxide (H2O2; 100 mM) for 30min at 37C after
which JC-1 orange and green fluorescence intensity was
measured for mitochondrial membrane potential with LSM
Carl Zeiss 510 Meta.
Mitochondrial volume estimation
HES2-VCMs were incubated at 37C with 0.1 mM Mito-
Tracker Deep Red and 0.1 mM Cell Tracker (Invitrogen)
for 30min for mitochondrial volume estimation. Stack im-
ages of mitochondria and cytoplasm were obtained with
LSM Carl Zeiss 510 Meta. Three-dimensional images of
HES2-VCMs were constructed and mitochondrial volume
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was estimated as % of total cell volume with the imaging
analysis software Imaris (Bitplane).
RNA extraction, cDNA synthesis, and gene
expression analysis by real-time PCR
Total RNA was extracted from samples using RNeasy
Mini Kit (Qiagen) following DNase I (Promega) treatment
for the removal of potential contamination of genomic
DNA. cDNA was prepared using the QuantiTect Rev.
Transcription Kit (Qiagen) following the manufacturer’s
protocol. Gene expression was quantified using StepOne-
Plus Real-Time PCR system (Applied Biosystems). PCR
amplification was carried out in 96-well optical plates con-
sisting of 100 ng of cDNA template, 5 pmol of forward and
reverse primers, and 1X KAPA SYBR Fast qPCR Master
Mix (KAPA Biosystems). The reactions were incubated at
95C for 3min, and followed by 40 cycles of 95C for 3 s,
and 60C for 20 s. GAPDH was used as internal control to
normalize loading and all reactions were performed in trip-
licate. Primers are listed in Supplementary Table S2.
Electrophysiological characterization
Electrophysiological experiments were performed using
the whole-cell patch-clamp technique as previously described
[20–22]. To profile chamber-specific subtypes of our hPSC-
derived CMs (hPSC-CMs), action potentials (APs) of the
myocytes were randomly probed at 37C with the patch-
clamp technique using an EPC-10 amplifier and Pulse software
(Heka Elektronik), with the current-clamp mode (0.1–0.5 nA
for 1–5ms) under the whole-cell configuration applied. The
hPSC-CMs were categorized into nodal, atrial, or ventricu-
lar like according to the standard AP parameters as we and
others previously described [17,20,21]. Voltage-clamp re-
cordings of ionic currents were performed using an auto-
mated parallel patch-clamp system (PatchXpress 7000A;
Molecular Devices) using standard electrophysiological and
FIG. 1. A highly efficient ven-
tricular cardiomyocyte (VCM) dif-
ferentiation system of human
pluripotent stem cells (hPSCs). (A)
Schematic of a direct differentia-
tion protocol used for the differ-
entiation of hPSCs to VCMs under
non-feeder and non-xenogeneic con-
ditions. Spontaneously contracting
clusters were detected as early as
day 8. (B) Images demonstrate typ-
ical culture morphology at different
time points of differentiation. Scale
bar= 200mm. Color images avail-
able online at www.liebertpub.com/
scd
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pharmacological protocols for isolating the ionic component
of interest (see Supplementary Data for details).
Ca2 + imaging
The intracellular Ca2 + ([Ca2 + ]i) transients were imaged
by a spinning disc laser confocal microscope (PerkinElmer)
on hPSC-CMs loaded with 1.5 mM X-Rhod-1 (Invitrogen) as
previously described [21]. After dye loading, experiments
were performed at 37C in Tyrode’s solution containing
140mM NaCl, 5mM KCl, 1mM MgCl2, 1.25mM CaCl2,
10mM HEPES, and 10mM d-glucose at pH 7.4. Electric
pulses (40ms pulse duration; 40V/cm; 1Hz) generated by a
field generator were continuously applied to pace electri-
cally induced Ca2 + transients (E[Ca2 + ]i). The amplitudes of
E[Ca2 + ]i are presented as the background-corrected pseudo
ratio (DF/F)= (F -Fbase)/(Fbase -B) where Fbase and F are
the measured fluorescence intensity before and after stim-
ulation, respectively, and B is the average background signal
from areas adjacent to the targeted cell. The transient rise
(Vupstroke) and the transient decay (Vdecay) were subsequently
calculated and analyzed.
Transplantation and in vivo tracking
of hESC-VCMs
H9DF cells stably expressing a double-fusion reporter gene
consisting of firefly luciferase and enhanced GFP [23,24]
were a kind gift from Dr. Joseph Wu and used for in vivo
monitoring of CM survival. Specifically, 2–3· 105 H9DF-
CMs were transplanted to the kidney capsule of NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ mice (6–10 weeks old). Transplanted
cell survival was longitudinally monitored via biolumines-
cence imaging (BLI) using the Xenogen in vivo imaging
system (Caliper Life Sciences). Briefly, mice were anesthe-
tized with isoflurane and D-Luciferin (Invitrogen) was ad-
ministrated intraperitoneally at a dose of 375mg/kg of body
weight. BLI signal was measured in maximum photons per
sec per centimeter square per steradian (p/s/cm2/sr). All
procedures performed were approved by the Committee on
the Use of Live Animals in Teaching and Research at the
University of Hong Kong. For detection of the transplanted
CMs, animals were killed at different time points and kidneys
were harvested and stained for the presence of cTnT-positive
cells (see Supplementary Data for details).
Statistical analysis
Data are presented as means – SEM. Student’s t-test or
ANOVA was used to measure statistical significance.
P < 0.05 is considered significant.
Results
Highly efficient ventricular specification of hESCs
We initially focused on HES2, the same hESC line that
Keller et al. employed for developing their original directed
differentiation protocols [1,3,25]. Our modified method for
ventricular specification is schematically summarized in
Figure 1A. To start, undifferentiated cells were seeded as
30,000 cells/cm2 for expansion in mTeSR1 medium for 4
days. On day 0, hPSCs were digested into single cells and
cultured in suspension in mTeSR1 medium with Matrigel
along with BMP4 (1 ng/mL) and ROCK (10mM) to induce
differentiation. After 24 h, the media was changed to
StemPro34 SFM with BMP4 (10 ng/mL), activin-A (10 ng/
mL), and AA (50 mg/mL) to induce the formation of car-
diogenic mesodermal EBs. As the last step, on day 4 when
nicely compact rounded aggregates could be observed,
IWR-1 (5 mM) was added to suppress Wnt signaling (Fig.
1B). As early as day 8, > 70% of hEBs from 30 out of
30 independent differentiation reactions became sponta-
neously contracting (eg, vs. *50% on days 10–12 of Keller
[3]; see Supplementary Video S1 and S2). On days 16–18,
*100% of hEBs were beating and, for the cTnT-positive
cells, about 17% were Ki67-positive proliferating (Supple-
mentary Fig. S1).
As anticipated, using real-time RT-PCR analysis, we de-
tected that the transcript expression of the pluripotency
markers OCT4 and Nanog decreased time dependently, and
rapidly became undetectable by days 4–5 (Fig. 2). By con-
trast, the transcript expression of T-box factor Brachyury (T)
and helix-loop-helix transcription factor mesoderm posterior
1 (MESP1), one of the earliest ‘‘cardiac’’ mesoderm markers,
transiently spiked during days 2–5 upon the addition of
BMP4 and activin-A. During the same time interval, the
cardiac progenitor marker Isl1 as well as the transcription
factors GATA4 and Hand1, critical for early cardiac differ-
entiation, also became expressed, with the early cardiac
progenitor marker Nkx2.5 appearing shortly after on d5 (after
IWR addition), peaked at day 8, and continued to remain high
beyond day 14. Consistent with a successful cardiac differ-
entiation, further analyses revealed that transcripts of sarco-
meric proteins, such as MYH6, MYH7, cTnT, and NPPA, that
are signatures of contractile CMs also had similar time-
dependent expression patterns. Expression levels ofML2Cv, a
marker of mature ventricular CMs, increased to a high level
at day 16 and remained so over 30 days. By contrast, the
expression of MLC2a, which is normally expressed in atrial
and immature ventricular CMs, peaked at day 16 and de-
clined afterward. The temporal transcript expression profiles
of the various pluripotency, mesodermal, and cardiac makers
are summarized in Figure 2.
hESC-CMs displayed a time-dependent switch
from MLC2a to MLC2v positive
To quantitate the efficiency of our specification protocol,
flow cytometry analysis was performed on differentiated
HES2 cells collected at days 16–18. As depicted in Figure
3A, the yield of cTnT+ cells was 90.8% for the represen-
tative reaction shown with an average of 87%– 3.4% for the
HES2 line (n = 6 independent reactions; Fig. 3B). Im-
munostaining experiments confirmed the subcellular ex-
pression of cardiac-specific proteins (ie, MLC2v, MLC2a,
MF20, a-actinin, and connexin 43) with the expected sar-
comeric structures (Fig. 4A), indicating that the derived
cells were hESC-CMs. As shown in Figure 4B, by day 20,
*85% of the differentiated cells were positively stained for
ML2Cv. Consistent with our qRT-PCR data, only*35% of
the MLC2v-positive cells were also positive for MLC2a
(Fig. 4B). By day 40, essentially all of HES2-VCMs did not
express MLC2a but only MLC2v (Fig. 4C), signifying that
the VCMs derived were amenable to maturation in vitro.
Considering the input of 300,000 hESCs at day 4, the output
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of our protocol as determined by flow cytometry was*32–
72 cTnT-positive cells per HES2 cell at day 14.
Functional characterization of hESC-VCMs
To confirm the functionality as well as chamber-specific
identity of our derived CMs, we next performed patch-
clamp recordings and Ca2 + imaging on 35–50-day-old
single cells isolated from cardiogenic EBs for examining
their electrophysiological profiles. Of the 42 HES2-CMs
recorded (from five independent batches), 93% displayed an
AP profile that was most consistent with the immature
ventricular type that we had previously published [17,21,26]
(Fig. 5A, D). Immature traits such as spontaneous AP firing,
a depolarized resting membrane potential or maximum di-
astolic potential, and phase 4 depolarization were readily
observed. AP parameters are summarized in Table 1. Con-
sistent with AP data, when unselected cells isolated from
HES2-EBs were immunostained with MLC2v and cTnT,
> 80% of the cells were doubly MLC2v and cTnT positive,
suggesting that our method supports a high percentage of
VCM differentiation (Fig. 5B). After zeocin selection, 100%
of LV-MLC2v-Tdtomato-T2A-zeocin–transduced cells dis-
played typical ventricular-like APs. Therefore, the cells de-
rived by our protocol were functional hESC-VCMs. As for
Ca2 + handling, Figure 5C shows that transients from these
cells had amplitudes and kinetics smaller and slower than
those of adults as we previously reported [27,28]. Further,
caffeine-induced Ca2 + was also observed, indicating a
functional sarcoplasmic reticulum. Upon isoproterenol (Iso)
application to our hESC-VCMs, a positive chronotropic
response with increased spontaneous AP and Ca2 + tran-
sient firings was observed. However, the transient amplitude
remained unchanged (P> 0.05), indicating a null iono-
tropic response to b-adrenergic stimulation. Moreover, a
live recording of the electrically induced Ca2 + transient
FIG. 2. Quantitative PCR-
basedgeneexpressionanalysis
of embryoid bodies (EBs) at
different stages of cardiac dif-
ferentiation. HES2 were
subjected to the cardiac differ-
entiation protocol described in
Figure 1. Expression levels of
pluripotent, cardiacmesoderm
markers, and cardiac specific
genes were normalized and
expressed relative to house-
keeping gene GAPDH. Plots
shown are representative of
three independent experiments.
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(Supplementary Video S3) recorded from a culture of iPSC-
CM also indicated the functional Ca2 + handling in the CMs.
When switched to the voltage-clamp mode, signature ven-
tricular ionic currents, such as voltage-dependent INa, L-type
ICa, IKr, sarcolemmal IKATP, could be recorded (Fig. 6),
electrophysiologically confirming the identity as VCMs.
Immature mitochondrial structure of HES2-VCMs
Others have reported that the structure of mitochondria
reflects various stages of cardiogenesis [29,30]. At day 30
post-differentiation, similar to embryonic/fetal CMs, HES2-
VCMs displayed a perinuclear mitochondrial structure, as
shown by staining with the mitochondrial COXIV-specific
antibody (Fig. 7A). In addition, the mitochondrial volume of
HES2-VCMs was 33.7%– 0.4% (n = 16) at day 30, smaller
than the reported value of 40% in human adult CMs [31].
Therefore, HES2-VCMs were more comparable to fetal
CMs that also carry a lower mitochondrial mass with peri-
nuclear localization compared with adult CMs [32]. We next
examined the mitochondrial inner membrane potential of
HES2-VCMs using the potential-sensitive JC-1 dye. Figure
7B shows the appearance of both green and red fluores-
cence HES2-VCMs, demonstrating the presence of both
depolarized (green monomer) and hyperpolarized (orange
aggregate) mitochondrial membrane potential. Areas of de-
polarized mitochondrial membrane potential were found in
the perinuclear region while areas of hyperpolarized po-
tential were mainly found at the perimeter of HES2-VCMs.
Similar to primary CMs, when subjected to oxidative stress
in the form of H2O2, hESC-VCMs showed a depolariza-
tion of their mitochondrial membrane potential (increase in
green vs. orange fluorescence) with JC-1 orange/green in-
tensity ratio decreased from 1.146 to 0.410.
FIG. 3. Specification of car-
diac differentiation in multiple
hPSC lines. (A) Representative
flow cytometry plots of cardiac
troponin T (cTNT)+ cells dif-
ferentiated from hPSCs. The
entire well of one 6-well plate
was enzymatically digested
into a single-cell suspension
and 100,000 cells were ana-
lyzed. (B) Percentages of
cTnT + cells in day 16–18
EBs of HES2, H7, H9DF, and
two nonviral CD34 + -derived
human induced PSC (hiPSC)
lines. Mean –SEM.
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Ventricular specification of additional hESC
lines and hiPSCs reprogrammed
from human CD34 + cells
Given that most methods for directed cardiac differenti-
ation reported to date require line-dependent optimizations
of growth factors [1,3,4,15], we next tested the versatility of
our protocol for consistent hPSC-VCM yields with different
lines. Indeed, we have previously reported that distinct
hESC lines have different cardiogenic potentials [33]. Such
differences can be further exemplified in hiPSCs, which are
known to display significant line-to-line and clone-to-clone
variability. Therefore, we generated hiPSCs from adult pe-
ripheral blood CD34 + cells using non-viral episomal vec-
tors (see Materials and Methods section). All our tested
hiPSC lines retained a normal karyotype, stained positively
for pluripotency markers by immunocytochemistry, and
expressed high levels of Oct4 and Rex1 (data not shown).
Differentiation into three germ layers was confirmed by
qRT-PCR and immunostaining. When injected subcutane-
ously into the immunodeficient mice, all tested hiPSC lines
formed teratomas consisting of the three primitive germ
layers (Supplementary Fig. S2). When these hiPSC lines
were subjected to ventricular specification by our protocols,
FIG. 4. Structural character-
ization of HES2-cardiomyocyte
(CM) by immunostaining.
(A) HES2-EBs were digested
into single cells at day 20
of differentiation and then
costained for MLC2v/MF20,
MLC2a/a-actinin, and con-
nexin 43/a-actinin. Nuclei were
counterstained with DAPI
(blue). Representative immu-
nostaining images for MLC2a
and MLC2v in HES2-CMs
examined at (B) day 20 and
(C) day 40 postdifferentia-
tion. Color images available
online at www.liebertpub
.com/scd
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spontaneously contracting cardiogenic EBs routinely emerged
on days 8–9 and achieved *80% cTnT + cells (Fig. 3),
which likewise expressed the cardiac markers cTnT, a-
actinin, and MLC2a with immature signature ventricular AP
and Ca2 + transients (Fig. 5). When tested with additional
hESC lines, H7 and H9DF, qualitatively similar data in terms
of time when beating EBs first appeared, % of cTnT+ cells,
APs, and Ca2 + transients were also consistently observed
(Figs. 3 and 5). Taken collectively, the yield of VCMs
ranged 92%–100% as gauged by APs (Fig. 5G). The re-
mainders were atrail-like hPSC-CMs (Fig. 5A). We did not
detect any nodal-like hPSC-CMs.
FIG. 5. Specification of ventric-
ular differentiation of hPSCs. (A)
Representative action potential
(AP) profiles of HES2-CMs, H7-
CMs, H9DF-CMs, iPSC-PB1-CMs,
and iPSC-PB2-CMs measured by
patch-clamp recordings. (B) Im-
munostaining of nonselected
HES2-CMs for MLC2v and cTnT
expression. HES2-EBs were di-
gested into single cells and then
reseeded for immunostaining with-
out any purification. Scale bar=
200 mm. (C) Representative Ca2+
transient tracings of HES2-VCMs
and iPSC-PB1-VCMs paced by
electrical field stimulation (1Hz,
40V/cm). All cells examined were
> 35 days old. (D) Percentages of
cells expressing VCM and atrial
cardiomyocyte (ACM) AP profiles
as detected by patch-clamping.
Color images available online at
www.liebertpub.com/scd
Table 1. Summarization of the Action Potential Properties of HES2-VCMs (n = 2)
Firing frequency (Hz) Amplitude (mV)
Upstroke velocity
(mV/ms)
Decay velocity
(mV/ms) APD50 (ms) APD90 (ms) MDP (mV)
1.59 – 0.03 94.0 – 0.4 8.85 – 0.31 - 0.76 – 0.01 443.0 – 8.4 571.4 – 9.0 - 72.5 – 0.2
VCMs, ventricular cardiomyocytes.
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Transplantation of hPSC-VCMs for in vivo studies
Previous transplantation studies of hESC-CMs almost
always involved cell mixtures with low yields of hESC-CMs
or heterogenous mixtures of V and other chamber-specific
types [24,34]. To test the in vivo survival of our hPSC-
VCMs, we employed our protocol to differentiate a H9 cell
line expressing the double-fusion GFP-luciferase proteins to
H9-VCMs [24]. Figure 8A shows that > 72% of cTnT+ cells
could be generated. After transplantation into the kidney
capsule of immunodeficient mice, cTnT+ cells remained
detected for least 27 days (Fig. 8B, C). Immunohistochem-
istry staining showed a localized region of cTnT-positive
cells in the transplanted kidney capsule (Fig. 8D). There-
fore, our robust differentiation of VCMs of hPSCs provides
a great cell source for future transplantation experiments.
Discussion
In the present study, we have made the following sa-
lient accomplishments: (i) a final output of*35–70 hPSC-
VCMs per hPSC (vs. 1–20 hPSC-CMs per hPSC, of which
merely a fraction was VCMs); (ii) a relatively simple and
cost-effective protocol that reproducibly generates cardiac
cells within a short time and requires the least amounts of
reagents (eg, bFGF and VEGF were not needed for ex-
pansion); (iii) the protocol is effective for multiple hESC
and hiPSC lines without the need of line-dependent opti-
mization; and (iv) ventricular specification of hESC/iPSCs,
as confirmed electrophysiologically by ventricular AP and
ionic currents. These results are further discussed in the fol-
lowing headings in relation other recent relevant studies.
Comparison with other directed cardiac
differentiation protocols
Recent advances in directed cardiac differentiation pro-
tocols have enabled the derivation of hESC/iPSC-CMs in
larger quantities. These protocols have generally adopted
the approach of sequential addition of growth factors. The
first major breakthrough was accomplished by Yang et al.
FIG. 6. Ionic currents (INa,
ICaL, IKr, and IKATP) in
HES2-CMs. Representative
(A) INa and (B) ICaL traces
elicited by voltage protocol
shown in inset. Middle: peak
I–V plots. Right: Steady-
state inactivation and activa-
tion relations. (n = 7). (C)
Representative IKr traces af-
ter the subtraction of E4031-
insensitive current elicited by
voltage protocol shown in
inset. (D) Activation rela-
tion of Ikr (n= 11). (E) Sar-
colemmal IKATP channels in
HES2-VCMs. Left panel: rep-
resentative tracings of sarco-
lemmal IKATP in HES2-VCMs
at 0mV under control con-
ditions (blue line), with so-
dium cyanide (CN, 2mM)
alone (black line), or with
CN and glibenclamide (GLI,
10mM; red line). Right panel:
summary of averaged current
densities under the same con-
ditions. Cells were stimulated
to 0mV for 1,000ms from a
holding potential of - 80mV
preceded by a 100-ms pre-
pulse to - 10mV (n= 5).
**P<0.01 compared with con-
trol group; ##P< 0.01 com-
pared with CN group. Color
images available online at
www.liebertpub.com/scd
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who developed a directed differentiation protocol of deriv-
ing hESC (HES2)-CMs via stage-specific addition of a
combination of activin-A, BMP4, FGF2, VEGF, and Dick-
kopf-1 (DKK-1) to generate a tripotent cardiovascular pro-
genitor population [3]. The method requires optimization on
the growth factor concentrations for different specific PSC
lines with the reported yield of > 50% of beating clusters.
Using this protocol, we could differentiate*40% of cTnT +
cells from HES2 cells, which heterogeneously consisted of a
mixture of ventricular, atrial, and pacemaker derivatives
(with a ratio of 42:53:5) [26]. The total output is therefore
*4 hPSC-CMs or 2.2 hPSC-VCMs per hPSC.
Burridge et al. optimized > 45 experimental variables to
develop a protocol with optimized concentrations of BMP4
and FGF2, polyvinyl alcohol, serum, and insulin for cardiac
differentiation of hESCs (H1 and H9) and hiPSC lines derived
from neonatal CD34+ CBs (CBiPSC6.2 and CBiPSC6.11) and
adult fibroblasts (iPS-IMR90-1) using nonintegrated episomal
plasmids to generate 64%–89% cTnT+ cells by day 9 [4]. The
derived CMs are functionally responsive to cardioactive drugs
when optically mapped as multicellular clusters. However, the
efficiency and AP profiles and distribution of the differentiated
CMs were not mentioned.
In the study by Lian et al., the investigators employ
glycogen synthase kinase 3 (GSK3) inhibitors combined
with the b-catenin shRNA or a chemical Wnt inhibitor to
produce a 80%–98% purity of functional CMs in 14 days
from hESCs (H9, H13, and H14) and multiple hiPSC lines
(6-9-9, 19-9-11, and IMR90C4) [12]. Similar to our findings
reported here, beating clusters are observed between days 8
and 10. About 20% of day-20 CMs are proliferative as in-
dicated by Ki67 staining or BrdU assay. The number of cells
generated by this protocol is 15 CMs per hPSC input
without any enrichment and/or purification step. The method
focuses on early induction of canonical Wnt signaling and
suppression of canonical Wnt signaling at later stages of
differentiation to synergistically enhance the CM yield.
Zhang et al. reported a matrix sandwich method by over-
laying monolayer-cultured hPSCs with Matrigel [2]. They
combined the matrix sandwich with sequential application
of activin-A, BMP4, and bFGF to generate a high purity of
up to 98% and a yield of up to 11 CMs/input PSC from
multiple PSC lines, including H1, H9, and three iPSC lines
derived from foreskin fibroblasts using nonintegrating
vectors and the lentiviral-generated iPS cell line IMR90
clone 4 (IMR90 C4). Atrial/ventricular distribution is not
reported.
Ren et al. reported early modulation of the BMP4 coupled
with late inhibition of Wnt signaling pathways in hiPSCs to
generate high efficiency of cardiac differentiation [14]. This
method, tested on H7 only, requires a high concentration of
serum (20%) but with a relatively low percentage of cTNT-
positive cells (*16%). AP profile is also not reported.
Minami et al. reported the use of a single small-molecule
KY02111 to promote hPSC differentiation into CMs with a
yield of up to 98% by inhibiting WNT signaling [13]. EP
data show that VCMs and pacemaker cells are present and
electrophysiologically functional. The method, tested on
four hiPSC lines, can be achieved in a serum- and xeno-free
condition to produce *4.2 · 106 hPSC-CMs from *6 to
· 106 seeded initially per well or 0.7 hPSC-CMs per hPSC.
Given that this method requires only a single small molecule
to direct CM differentiation, it is by far the simplest pro-
tocol. The ventricular yield is unknown.
Comparison with our recent ventricular
specification protocol
The present method differs from our recently published
protocol [35] in several ways. First, here we used ROCK
and Matrigel instead of Blebbistatin on day 0. Second, 10-
fold less of BMP4 was used on day 0 and 2.5-fold less of
activin-A was added on day 1 in our protocol. Third, our
cells were digested by Accutase into single cells on day 0, as
FIG. 7. Immature mitochondrial structure of HES2-VCMs.
(A) Lentivirus (LV)-MLC2v-Tdtomato-T2A-Zeo–transduced
and Zeo-selected HES2-VCMs (30–50 days old) were im-
munostained for a-actinin and mitochondrial cytochrome c
oxidase (COX)IV. Nuclei were counterstained with DAPI
(blue). Scale bar= 25mm. (B) HES2-VCMs were stained
using the potential-sensitive JC-1 dye. Left panel shows
representative image of control cells with both green and red
fluorescence in the HES2-VCMs. Right panel shows repre-
sentative image of HES2-VCMs subjected to 100mM hy-
drogen peroxide (H2O2) (n= 3). Scale bar= 100mm. Color
images available online at www.liebertpub.com/scd
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opposed to small clusters in the other protocol. Fourth, there
was no media change on day 3, instead of changing to
StemPro +AA with IWR on day 4. Fifth, IWR-1 was added
on day 4 at 5 mM, instead of 2.5 mM on day 4.5. Finally, our
cells were maintained in normoxia and differentiated in
hypoxia between days 0 and 8 (vs. maintenance of undif-
ferentiated cells under hypoxia but differentiation under
normoxic condition, ie, the exact opposite). Collectively,
while the purity and % of PSC-VCMs are comparable, the
present yield and efficiency were higher. Although we
previously did not report the efficiency, the present protocol
provides*5 ·more cTNT-positive or PSC-VCMs per PSC.
Assuming 300,000 hESCs on day 4, the new protocol gen-
erates up to 72 cTNT-positive cells per HES2 cell (vs. 13
cTnT-positive cells per undifferentiated cell). We have now
also expanded to include additional lines.
Conclusion
Recent differentiation methods have led to higher CM
yields compared to traditional spontaneous differentiation
protocols. However, many require optimization of multiple
growth factors for different hPSC lines, with variability
often seen with hiPSC lines. Our method does not require
an optimization between activin-A and BMP4; the same
concentrations of activin-A and BMP4 were used for all
the different hESC and hiPSC lines tested but both the
efficiency for ventricular specification remains consistently
high. Further, most data are reported as the percentage of
contracting EBs. Since EBs contain non-CMs and single-
cell assays were not performed, the ventricular yields
are not known. Further, the percent yield of ventricular
CMs compared with other chamber-specific types is often
not reported. In sum, our protocol reported here represents
a cost-effective, reproducible, and straightforward VCM
specification method for hESC and hiPSC lines. These
results may lead to mass production of hPSC-VCMs on a
suitable scalable platform (eg, bioreactors and micro-
carriers).
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